Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding. Led by CEO Jim Burns, Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through in vivo hematopoietic stem cells (HSCs) engineering. Its platform combines proprietary base editing or gene integration systems with high-capacity virus-like particles (VLPs) toward our goal of providing one-time administration of durable genetic medicines. The delivery system is based on VLPs that preferentially bind to HSCs, delivering DNA to the nucleus. With a 35-kilobase cargo capacity, these VLPs can carry a diverse range of sophisticated genomic engineering tools capable of introducing changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression.